ASPHO Webinars Connect Learners to the Latest in Pediatric Hematology/Oncology Clinical Treatment, Best Practices, and Professional Development
ASPHO and its partners create presentations led by experts in clinical and career topics of broad interest to pediatric hematology/oncology specialists. Webinar attendees can participate live and ask presenters and moderators questions, or they can watch a recorded version after the event. Stay informed with convenient, on-demand education designed for today's pediatric hematology/oncology practitioner.
Hear what attendees say about ASPHO Webinars:
"Great information sharing and something that I can definitely take back to my team."
"Wonderful, informative, useful information!"
About ASPHO Webinars
Webinars are live programs and are also available on-demand; free to members and available for purchase to nonmembers. Each webinar is an hour-long, with 45 minutes of lecture and 15 minutes of live Q&A. Past webinars can be accessed through the Products page.
2026 - 2027 Webinar Series
Monday, September 28 - A Day in the Life of Peds Hematology/Oncology in a Small Program: A Panel Discussion (Developed by the Small Program SIG)
Monday, October 26 - Harnessing Immunity Without Harm" - Part 1: The Price of Suppression: Immunosuppressant Toxicities and Monitoring (Developed by the Clinical Immunology SIG)
Monday, November 2 - Harnessing Immunity Without Harm" - Part 2: Immune Storms and Checkpoint Pitfalls: Immune-Related Adverse Events of Novel Immunotherapies (Developed by the Clinical Immunology SIG)
Monday, December 7 - From Burnout to Well-Being: The Role of Communication (Developed by the Well-Being and APP SIG)
2025 - 2026 Webinar Series
Register for On-Demand Viewing
Recorded Webinar - Fertility Preservation in Adolescent and Young Adult (AYA) Oncology Patients
With contemporary cancer therapy, survival for AYA patients exceeds 80%. Unfortunately, the therapy required to cure cancer often has short- and long-term health consequences. One of these long-term toxicities is a negative impact on a cancer survivor’s fertility. There used to be few options available, but with greater awareness, earlier interventions, and improved reproductive technologies, our patients have options for fertility preservation before starting therapy and during survivorship. This webinar will review the impact of cancer and treatment on fertility, including the modalities of chemotherapy, surgery, and radiation. It will then educate the audience about the choices patients with cancer have to preserve fertility before therapy and to restore fertility when they are survivors. The speakers will review both standards of care and experimental approaches to this important problem. We will examine the barriers to the broader use of these techniques and identify strategies to overcome these barriers so that more cancer survivors will be able to have children if they so choose.
Learning Objectives
- Understand the impact that cancer and cancer therapy can have on future fertility in AYA oncology patients,
- Describe modern fertility preservation techniques that can be used in these patients,
- Identify the barriers to the use of these techniques and explore local and national strategies to overcome them.
Speakers
Pinki Prasad, MD MPH (moderator)
Jennifer L. Reichek, MD MSW
Karen C. Burns, MD MS
Jennifer M. Levine, MD
The webinar features a lecture presentation followed by recorded Q/A with the presenters. Once registered, access to the recorded webinar will be provided in your ASPHO My Library. Please contact ASPHO Member Services at This email address is being protected from spambots. You need JavaScript enabled to view it. or by calling 847.375.4716 with any questions.
Recorded Webinar - Active Music Engagement (AME): A New Standard for Reducing Stress in Pediatric Cancer Families (Developed by the ASPHO Integrative SIG)
Cancer and its related treatment are highly stressful and potentially traumatic life events for young children with cancer and their parents. Active Music Engagement (AME) is a music therapist-delivered intervention that uses music-based play to address the interrelated distress experienced by young children (ages 3-8 years) and their parents. Findings from two NIH-funded mechanistic trials indicate that AME can significantly lower child distress and fatigue and buffer traumatic stress symptoms in parents during cancer treatment. Mediation analyses indicate the importance of parent-child interaction as a significant pathway for improved well-being. Moderation analyses indicate AME is particularly beneficial for parents who screen high for traumatic stress and who report higher distress in their child, supporting AME as an evidence-based intervention to address the needs of our most highly distressed parents and children.
Learning Objectives
- Describe key theoretical concepts that inform the Active Music Engagement intervention
- Identify benefits of AME for young children and parents
- Define the role of music engagement and parent-child interaction as an important mediator of parent well-being and lower traumatic stress symptoms
Speakers
Karen Moody, MD (moderator)
Sheri L. Robb, PhD, MT-BC
The webinar features a lecture presentation followed by recorded Q/A with the presenters. Once registered, access to the recorded webinar will be provided in your ASPHO My Library. Please contact ASPHO Member Services at This email address is being protected from spambots. You need JavaScript enabled to view it. or by calling 847.375.4716 with any questions.
Recorded Webinar - Advances in the Management of Retinoblastoma
Retinoblastoma care continues to advance and evolve, with increasing rates of globe salvage being achieved. Excellent Retinoblastoma care is best provided by a multidisciplinary team. This webinar will review the advances in current Retinoblastoma care and strategies to achieve this with a team approach.
Learning Objectives
- Highlight current diagnostic tools used in Retinoblastoma (RB)
- Review current pathology standards for RB
- Describe treatment considerations for RB, including perspectives from both a pediatric oncologist and ocular oncologist
Speakers
Kerri Becktell, MD, MS (moderator)
Aparna Ramasubramanian, MD
Nicole Liberio, MD, MS
Amanda Hopp, MD
The webinar features a lecture presentation followed by recorded Q/A with the presenters. Once registered, access to the recorded webinar will be provided in your ASPHO My Library. Please contact ASPHO Member Services at This email address is being protected from spambots. You need JavaScript enabled to view it. or by calling 847.375.4716 with any questions.
Recorded Webinar - The Evolution of Pediatric Hematology/Oncology APP Practice Demands to Meet Organizational Needs with Changing ACGME Requirements
Access the Recorded Webinar: — Complimentary Access!
The Pediatric Hematology/Oncology practice environment is ever evolving and further specializing, increasing the demand for specialized and dynamic advanced practice providers (APPs) to meet patient care needs. As ACGME requirements change, organizations need to adapt and commonly fill gaps with APPs. Learn how different types of organizations and their structure types have evolved to meet these changes, as well as learning and training methodologies implemented to meet these new demands.
Learning Objectives
- Evaluate specific organizational APP needs to address gaps provided by changing ACGME requirements
- Determine APP practice structure necessary to meet organization/HemOnc program needs and address changes in ACGME requirements
- Identify APP education and training gaps and implement appropriate resources to address gaps
Speakers
Lea Mayer, DNP APRN CPNP-PC CPHON (moderator)
Heather Johnson, MSN APRN CNP
Kelly Kramer, APRN MSN CPNP-PC CPON
Kara Kelly, MSN APRN CPNP-AC
The recorded webinar features a lecture presentation followed by recorded Q/A with the presenters. Once registered, access to the recorded webinar will be provided in your ASPHO My Library. Please contact ASPHO Member Services at This email address is being protected from spambots. You need JavaScript enabled to view it. or by calling 847.375.4716 with any questions.
Recorded Webinar - Bridging the Gap: Transitional Care for AYA Individuals with Sickle Cell Disease
As individuals with sickle cell disease (SCD) live longer due to advances in pediatric care, the need for high-quality, developmentally appropriate transitional care has never been more critical. This webinar will explore best practices, persistent challenges, and innovative models in transitioning adolescents and young adults with SCD from pediatric to adult healthcare systems.
Led by dual-trained pediatric and adult hematologists with expertise in lifespan SCD care, this session will examine key elements of successful transition programs—including readiness assessments, interdisciplinary collaboration, and patient centered education. We'll also discuss systemic barriers such as healthcare inequities, insurance instability, and workforce limitations, and highlight strategies to promote continuity, trust, and engagement during this vulnerable period.
Participants will gain a deeper understanding of how to support young adults with SCD as they navigate complex medical and psychosocial changes, and how to advocate for structural improvements in their institutions. Designed for clinicians, trainees, and healthcare leaders, this session aims to inspire collaborative efforts to reimagine transitional care as a bridge—not a barrier —to lifelong wellness.
Learning Objectives
- Understand the challenges of transitioning AYA patients with sickle cell disease to adult care.
- Appreciate interventions that can be used to assist in transition.
- Learn about metrics that can measure success of transition.
Speakers
Jane Hankins, MD MS (moderator)
Tarun Aurora, MD MSCI
Melissa Azul, DO
Stephanie Guarino, MD
The webinar will feature a lecture presentation followed by live Q/A with the presenters. During the webinar, please submit questions using the Q/A tab. Webinar registration also includes access to the recording on-demand after the live event. Please contact ASPHO Member Services at This email address is being protected from spambots. You need JavaScript enabled to view it. or by calling 847.375.4716 with any questions.
Recorded Webinar - The Next Chapter: Evolving Roles and Reflections in Pediatric Hematology/Oncology
As pediatric hematology/oncology (PHO) physicians approach the later stages of long and meaningful careers, an important question often goes unaddressed: What comes next? Despite decades of clinical, academic, and leadership contributions, there are limited opportunities within our field to discuss how to continue contributing meaningfully, intentionally transition roles, or thoughtfully prepare for retirement. Most professional organizations, including ASPHO, emphasize early- and mid-career development, leaving a gap in programming and mentorship for physicians practicing 25 years or more.
To better understand the needs of this cohort, we convened a focus group of late-career PHO physicians to identify gaps in mentorship and professional support. These insights informed a subsequent needs assessment distributed to mid-late and late-career members. The results of this assessment will be shared during this webinar and will serve as a springboard for a personal and reflective discussion with two late-career pediatric hematologist/oncologists who have pursued different end-of-career pathways.
This webinar will foster professional and personal well-being by normalizing conversations about late-career transitions, sharing diverse experiences, and generating ideas for future programming focused on mentorship, community, and ongoing professional engagement. The session will include brief slide presentations, followed by a moderated panel discussion and interactive Q&A.
Learning Objectives
- Describe the gaps in mentorship opportunities and professional support for late career PHO physicians by reviewing the results of the recently distributed needs assessment
- Share personal experiences from two distinct perspectives regarding career transitions and retirement planning
- Identify strategies for ASPHO to develop late career mentorship opportunities and foster a community of shared experiences
Speakers
Adit Tal, MD (moderator)
Dana Matthews, MD
Amanda Termuhlen, MD
The webinar will feature a lecture presentation followed by live Q/A with the presenters. During the webinar, please submit questions using the Q/A tab. Webinar registration also includes access to the recording on-demand after the live event. Please contact ASPHO Member Services at This email address is being protected from spambots. You need JavaScript enabled to view it. or by calling 847.375.4716 with any questions.
Sponsored Webinar
Replacing What’s Missing: The Role of Single-Factor Replacement Therapy in the Management of Hereditary Factor X Deficiency (HFXD)
Tuesday, September 1, 2026, 7:00pm CDT
Speaker:
Tammuella Chrisentery- Singleton, MD
Program Synopsis:
This program will focus on an ultra-rare bleeding disorder, Hereditary Factor X Deficiency (HFXD). Attendees will learn more about this severe bleeding disorder, including symptoms, testing, and unique severity scale. During this session, Dr. Singleton will also discuss the burden of disease, current treatment landscape, considerations for patient management, and the role of single-factor replacement, COAGADEX, in the treatment of HFXD.
Register Here: https://app.smartsheet.com/b/form/019e177195b27ebc89b48ef8466167f4
Indications and Usage for COAGADEX
COAGADEX, a plasma-derived blood coagulation factor X concentrate, is indicated in adults and children with hereditary factor X deficiency for:
- Routine prophylaxis to reduce the frequency of bleeding episodes
- On-demand treatment and control of bleeding episodes
- Perioperative management of bleeding in patients with mild, moderate and severe hereditary factor X deficiency
Contraindication for COAGADEX
COAGADEX is contraindicated in patients who have had life-threatening hypersensitivity reactions to COAGADEX.
Important Safety Information for COAGADEX
Allergic type hypersensitivity reactions, including anaphylaxis, are possible with COAGADEX. If symptoms occur, patients should discontinue use of the product immediately, contact their physician, and administer appropriate treatment.
The formation of neutralizing antibodies (inhibitors) to factor X is a possible complication in the management of individuals with factor X deficiency. Carefully monitor patients taking COAGADEX for the development of inhibitors by appropriate clinical observations and laboratory tests.
COAGADEX is made from human plasma and may contain infectious agents, e.g. viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. No cases of transmission of viral diseases, vCJD or CJD, have been associated with the use of COAGADEX.
In clinical studies, the most common adverse reactions (frequency ≥5% of subjects) with COAGADEX were infusion site erythema, infusion site pain, fatigue and back pain.
Please see complete Prescribing Information for COAGADEX. (link to https://www.coagadexhcp.com/prescribing-information)
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit https://www.fda.gov/medwatch, or call 1-800-FDA-1088.
You may also call Kedrion at 1-866-398-0825 or email This email address is being protected from spambots. You need JavaScript enabled to view it. .

